Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 11.99B 10.27B 9.58B 8.79B 16.52B 1,148B 16.84B 114B 44.31B 575B 45.03B 44.05B 1,904B P/E 2026 *
-82.2x
P/E 2027 * 82.5x
Enterprise Value 11.47B 9.82B 9.16B 8.41B 15.8B 1,097B 16.11B 109B 42.37B 550B 43.06B 42.13B 1,821B EV / Sales 2026 *
7.51x
EV / Sales 2027 * 5.15x
Free-Float
94.13%
Yield 2026 *
-
Yield 2027 * -
1 day-3.90%
1 week+2.31%
Current month+11.08%
1 month-3.10%
3 months+1.09%
6 months+19.33%
Current year-10.86%
1 week 506.84
Extreme 506.845
542.78
1 month 447.01
Extreme 447.01
566.18
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 8.74
Extreme 8.74
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
15/8/26 Free

Director

1,725 0.0075%
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
17/6/26 Free

Director

1,220 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
-3.90%+2.31%+32.54%+188.80% 11.99B
+2.38%+3.43%+82.88%+115.89% 73.96B
-0.14%+21.01%+53.40%+93.73% 64.66B
-4.27%-0.99%-3.38%+475.61% 27.32B
-1.97%+20.38%-0.37%+0.48% 27.86B
+2.24%+12.65%+62.36%+27.76% 25.97B
-0.47%+5.13%+35.39%-14.59% 19.98B
-1.79%-4.84%+239.54%+414.48% 17.84B
+0.75%+3.27%+18.44%+532.35% 16.24B
-1.29%+6.09%+41.81%+154.45% 13.3B
Average -0.82%+5.80%+56.26%+198.90% 29.91B
Weighted average by Cap. -0.12%+7.97%+57.92%+161.90%

Financials

2026 *2027 *
Net sales 1.53B 1.31B 1.22B 1.12B 2.1B 146B 2.14B 14.46B 5.64B 73.19B 5.73B 5.61B 242B 2.14B 1.84B 1.71B 1.57B 2.95B 205B 3.01B 20.33B 7.92B 103B 8.05B 7.88B 341B
Net income -184M -157M -147M -135M -253M -17.59B -258M -1.74B -679M -8.82B -690M -675M -29.19B 200M 171M 160M 147M 275M 19.14B 281M 1.9B 739M 9.59B 751M 735M 31.75B
Net Debt -525M -449M -419M -384M -722M -50.19B -737M -4.97B -1.94B -25.15B -1.97B -1.93B -83.27B -943M -808M -753M -691M -1.3B -90.25B -1.32B -8.94B -3.48B -45.23B -3.54B -3.46B -150B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
20/08/26 US$519.09 -3.90% 264,483
19/08/26 US$540.16 +3.01% 221,134
18/08/26 US$524.37 -0.10% 356,197
17/08/26 US$524.87 +3.41% 307,441
14/08/26 US$507.56 +0.04% 234,655
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
519.09USD
Average target price
678.06USD
Spread / Average Target
+30.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock